Novavax (NVAX)
NASDAQ:NVAX

Novavax (NVAX) Stock Forecast & Price Target

7,799 Followers
See the Price Targets and Ratings of:

NVAX Analyst Ratings

Hold
4Ratings
2 Buy
0 Hold
2 Sell
Based on 4 analysts giving stock ratings to
Novavax
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NVAX Stock 12 Months Forecast

Average Price Target

$54.25
▲(208.06% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Novavax in the last 3 months. The average price target is $54.25 with a high forecast of $100.00 and a low forecast of $16.00. The average price target represents a 208.06% change from the last price of $17.61.
Highest Price Target$100.00Average Price Target$54.25Lowest Price Target$16.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Cowen & Co.
$110.00
Buy
524.65%
Upside
Reiterated
Cowen Co. Maintains Outperform on Novavax, Lowers Price Target to $110
H.C. Wainwright
$207.00
Buy
1075.47%
Upside
Reiterated
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novavax (NASDAQ: NVAX) and PharmaCyte Biotech (NASDAQ: PMCB)
Cantor Fitzgerald
$168.00
Buy
854.00%
Upside
Reiterated
Novavax Whale Trades For June 24Cantor Fitzgerald has decided to maintain their Overweight rating on Novavax, which currently sits at a price target of $168.
Evercore ISI
Buy
Upgraded
Yellen Says Inflation Is Here to Stay While Target Is Cutting Prices. Theyre Not at Odds. | BarronsTreasury Secretary Janet Yellen is raising the White Houses forecast for inflation and says she expects it to remain high.
CFRA Analyst forecast on NVAX
Unknown Analyst
Not Ranked
CFRA
$71.00
Buy
303.18%
Upside
Upgraded
CFRA upgrades Novavax (NVAX) to BuyCFRA upgraded Novavax (NASDAQ: NVAX) from Hold to Buy with a price target of $71.00 (from $57.00).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

NVAX Financial Forecast

NVAX Earnings Forecast
Next quarter’s earnings estimate for NVAX is -$1.10 with a range of -$1.88 to -$0.46. The previous quarter’s EPS was -$2.15. NVAX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.45% of the time in the same period. In the last calendar year NVAX has Underperformed its overall industry.
Next quarter’s earnings estimate for NVAX is -$1.10 with a range of -$1.88 to -$0.46. The previous quarter’s EPS was -$2.15. NVAX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.45% of the time in the same period. In the last calendar year NVAX has Underperformed its overall industry.
NVAX Sales Forecast
Next quarter’s sales forecast for NVAX is $375.22M with a range of $329.00M to $402.70M. The previous quarter’s sales results were $628.30M. NVAX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 42.90% of the time in the same period. In the last calendar year NVAX has Underperformed its overall industry.
Next quarter’s sales forecast for NVAX is $375.22M with a range of $329.00M to $402.70M. The previous quarter’s sales results were $628.30M. NVAX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 42.90% of the time in the same period. In the last calendar year NVAX has Underperformed its overall industry.
NVAX Analyst Recommendation Trends
In the current month, NVAX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NVAX average analyst price target in the past 3 months is $54.25
In the current month, NVAX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NVAX average analyst price target in the past 3 months is $54.25

NVAX Stock Forecast FAQ

What is NVAX’s average 12-month price target, according to analysts?
Based on analyst ratings, Novavax’s 12-month average price target is $54.25.
    What is NVAX’s upside potential, based on the analysts’ average price target?
    Novavax has 208.06% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NVAX a Buy, Sell or Hold?
          Novavax has a conensus rating of Hold which is based on 2 buy ratings, 0 hold ratings and 2 sell ratings.
            What is Novavax’s price target?
            The average price target for Novavax is $54.25. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $100.00 ,the lowest forecast is $16.00. The average price target represents 208.06% Increase from the current price of $17.61.
              What do analysts say about Novavax?
              Novavax’s analyst rating consensus is a ‘Hold. This is based on the ratings of 4 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis